Stocks Health care ABVC

NASDAQ · Health care

Abvc Biopharma, Inc. (ABVC)

It posted a net loss of $7.1M. At June 30, 2026 it held $31.9K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.

Watch ABVC in 60 seconds

Follow ABVC

Free, no password. An email when ABVC files with the SEC.

Key facts about Abvc Biopharma, Inc.

Net worth

Abvc Biopharma, Inc. has a market value (market cap) of $26.4M at the latest share price, and shareholders' equity of $10.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Revenue and profit

In fiscal 2025 revenue was $296K (-41.9% year on year), with a net loss of $7.9M.

Cash flow

In fiscal 2025 operations used $3M of cash.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR

What Abvc Biopharma, Inc. does

Abvc Biopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ABVC.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Where ABVC ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Abvc Biopharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 29, 2026
   Proxy statement DEF 14A
2. September 11, 2026
   Form PRER14A filing PRER14A
3. August 27, 2026
   Acquisition or sale completed 8-K
4. August 25, 2026
   Form PRER14A filing PRER14A
5. August 12, 2026
   Form PRER14A filing PRER14A
6. August 12, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.03 versus -$0.13.
7. August 12, 2026
   Other event 8-K/A
8. August 4, 2026
   Other event 8-K
9. July 28, 2026
   Preliminary proxy statement PRE 14A
10. July 2, 2026
    Auditor change 8-K

Recent insider filings (Forms 3, 4 and 144): 2, the latest on July 12, 2022. Insider transactions on SEC

Insider trades

What the people running Abvc Biopharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns ABVC

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Lind Global Fund II LP 3.2% (August 13, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about ABVC

What does Abvc Biopharma, Inc. do?

Abvc Biopharma, Inc. is a company in the Health care sector, listed on NASDAQ as ABVC. Its shares trade on NASDAQ under the ticker ABVC.

What is Abvc Biopharma, Inc.'s net worth?

Abvc Biopharma, Inc. has a market value (market cap) of $26.4M at the latest share price, and shareholders' equity of $10.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Abvc Biopharma, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $7.1M.

When did Abvc Biopharma, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the proxy statement from September 29, 2026.

Similar companies

Compare ABVC with

Compare ABVC with any company

Follow ABVC

Get an email when Abvc Biopharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ABVC

Free, no password. An email when ABVC files with the SEC.

Where the numbers come from

Financial figures are the values Abvc Biopharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.